These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30710067)

  • 1. A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction.
    Gong J; Cho M; Gupta R; Synold TW; Frankel P; Ruel C; Fakih M; Chung V; Lim D; Chao J
    Oncologist; 2019 Aug; 24(8):1137-1145. PubMed ID: 30710067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms.
    Gusella M; Pasini F; Caruso D; Barile C; Modena Y; Fraccon AP; Bertolaso L; Menon D; Crepaldi G; Bononi A; Spezzano R; Telatin GA; Corona G; Padrini R
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):493-500. PubMed ID: 30542768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
    Schaaf LJ; Hammond LA; Tipping SJ; Goldberg RM; Goel R; Kuhn JG; Miller LL; Compton LD; Cisar LA; Elfring GL; Gruia G; McGovren JP; Pirotta N; Yin D; Sharma A; Duncan BA; Rothenberg ML
    Clin Cancer Res; 2006 Jun; 12(12):3782-91. PubMed ID: 16778106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.
    Takebe N; Beumer JH; Kummar S; Kiesel BF; Dowlati A; O'Sullivan Coyne G; Piekarz R; Rubinstein L; Fogli LK; Vaishampayan U; Goel S; O'Bryant CL; El-Rayes BF; Chung V; Lenz HJ; Kim R; Belani CP; Tuscano JM; Schelman W; Moore N; Doroshow JH; Chen AP
    Br J Clin Pharmacol; 2019 Nov; 85(11):2499-2511. PubMed ID: 31271459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor.
    Yang SH; Lin CC; Lin ZZ; Tseng YL; Hong RL
    Invest New Drugs; 2012 Feb; 30(1):282-9. PubMed ID: 20809205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
    Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.
    Saif MW; Rosen L; Rudek MA; Sun W; Shepard DR; Becerra C; Yamashita F; Bebeau P; Winkler R
    Br J Clin Pharmacol; 2019 Jun; 85(6):1239-1246. PubMed ID: 30628113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens.
    Blancas I; Aguirre E; Morales S; Gonzálvez ML; Servitja S; Díaz N; Del Barco S; Barnadas A; Margelí M; García Carbonero I; Llombart A
    Clin Transl Oncol; 2019 Apr; 21(4):459-466. PubMed ID: 30293232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
    Bartsch V
    Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.
    Abraham J; Edgerly M; Wilson R; Chen C; Rutt A; Bakke S; Robey R; Dwyer A; Goldspiel B; Balis F; Van Tellingen O; Bates SE; Fojo T
    Clin Cancer Res; 2009 May; 15(10):3574-82. PubMed ID: 19417029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study.
    Chattopadhyay N; Riecke K; Ligges S; Zimmermann T; Halabi A; Schultze-Mosgau MH
    Br J Clin Pharmacol; 2019 Sep; 85(9):2011-2021. PubMed ID: 31112623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study.
    Kitzen JJ; Puozzo C; de Jonge MJ; Brandely M; Verweij J
    Eur J Cancer; 2010 Jan; 46(2):266-9. PubMed ID: 19944596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
    Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
    Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC).
    Bonneterre J; Chevalier B; Focan C; Mauriac L; Piccart M
    Ann Oncol; 2001 Dec; 12(12):1683-91. PubMed ID: 11843245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of vinorelbine in patients with liver metastases.
    Robieux I; Sorio R; Borsatti E; Cannizzaro R; Vitali V; Aita P; Freschi A; Galligioni E; Monfardini S
    Clin Pharmacol Ther; 1996 Jan; 59(1):32-40. PubMed ID: 8549031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world.
    Pasini F; Barile C; Caruso D; Modena Y; Fraccon AP; Bertolaso L; Menon D; La Russa F; Crepaldi G; Bononi A; Spezzano R; Padrini R; Corona G; Gusella M
    Invest New Drugs; 2018 Oct; 36(5):927-932. PubMed ID: 29956056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis.
    Pétain A; Zhong D; Chen X; Li Z; Zhimin S; Zefei J; Zorza G; Ferré P
    Cancer Chemother Pharmacol; 2019 Aug; 84(2):373-382. PubMed ID: 31134323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study.
    Biakhov MY; Kononova GV; Iglesias J; Desai N; Bhar P; Schmid AN; Loibl S
    Expert Opin Drug Saf; 2010 Jul; 9(4):515-23. PubMed ID: 20500029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
    Ramanathan RK; Egorin MJ; Takimoto CH; Remick SC; Doroshow JH; LoRusso PA; Mulkerin DL; Grem JL; Hamilton A; Murgo AJ; Potter DM; Belani CP; Hayes MJ; Peng B; Ivy SP;
    J Clin Oncol; 2008 Feb; 26(4):563-9. PubMed ID: 18235115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.
    Abou-Alfa GK; Lewis LD; LoRusso P; Maitland M; Chandra P; Cheeti S; Colburn D; Williams S; Simmons B; Graham RA
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):29-36. PubMed ID: 28523596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.